Lucid Diagnostics consummates $11.1M senior secured convertible note with accredited investor

Lucid Diagnostics Inc.

Closed sale of up to $11,111,110 Senior Secured Convertible Note to an accredited investor as of March 21, 2023.
Entered into Registration Rights Agreement to register resale of shares underlying the Note; filing deadline 45 days post-closing.
Parent company PAVmed Inc. (holds ~72% of common stock) agreed via Voting Agreement to vote shares in favor of stockholder resolutions.
Note convertible into common stock; proceeds from private placement provide additional capital to Lucid Diagnostics.

item 1.01 item 2.03 item 3.02 item 3.03 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.